Vedolizumab does not increase perioperative surgical complications in patients with inflammatory bowel disease, cohort study

BACKGROUND/AIMS: Biologics are increasingly used to manage ulcerative colitis (UC) and Crohn’s disease (CD). However, even with earlier usage of biologic therapy, a significant proportion of patients will require surgery. Vedolizumab is an anti-integrin antibody that is increasingly used given that...

Descripción completa

Detalles Bibliográficos
Autores principales: Poylin, Vitaliy Y., Serrato, Jose Cataneo, Pastrana Del Valle, Jonathan, Feuerstein, Joseph D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Association for the Study of Intestinal Diseases 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8831769/
https://www.ncbi.nlm.nih.gov/pubmed/33525861
http://dx.doi.org/10.5217/ir.2020.00117

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8831769/
https://www.ncbi.nlm.nih.gov/pubmed/33525861
http://dx.doi.org/10.5217/ir.2020.00117

Ejemplares similares